Healthcare Industry News: Mylan
News Release - March 23, 2007
Pfizer Announces Launch of Generic Amlodipine Besylate Product by GreenstoneNEW YORK--(HSMN NewsFeed)--In response to an announcement today by Mylan Laboratories that it has launched a generic competitor to Norvasc, Pfizer said it is making available its own generic amlodipine besylate product immediately through the company's Greenstone subsidiary. Norvasc also will remain available to patients.
Pfizer said it will continue to pursue all available legal remedies to protect the market for Norvasc through a six-month pediatric exclusivity period that expires in September, 2007.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsPfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain
AbbVie Announces HUMIRA(R) (adalimumab) Global Patent License with Pfizer
Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer